Inhaled Drugs and Systemic Corticosteroids for Bronchopulmonary Dysplasia

被引：7
|
作者：
Bassler, Dirk [1 ]
van den Anker, John [2 ,3 ]
机构：
[1] Univ Zurich, Univ Hosp Zurich, Dept Neonatol, Frauenklin Str 10, CH-8091 Zurich, Switzerland
[2] Univ Basel, Div Paediat Pharmacol & Pharmacometr, Childrens Hosp, Spitalstr 33, CH-4056 Basel, Switzerland
[3] Childrens Natl Med Ctr, Div Clin Pharmacol, 111 Michigan Ave NorthWest, Washington, DC 20010 USA
来源：
PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 06期
关键词：
Bronchopulmonary dysplasia; Inhaled corticosteroids; Inhaled bronchodilators; Systemic corticosteroids; Dexamethasone; Hydrocortisone; Pharmacology; CHRONIC LUNG-DISEASE; LOW-DOSE HYDROCORTISONE; PRETERM INFANTS; PREMATURE-INFANTS; RANDOMIZED-TRIAL; CEREBRAL-PALSY; DOUBLE-BLIND; PREVENTION; THERAPY; PHARMACOKINETICS;
D O I：
10.1016/j.pcl.2017.08.012
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
All definitions of bronchopulmonary dysplasia (BPD) have limitations, and a new definition for the purpose of clinical research, benchmarking, and prognostic prediction is needed. Different inhaled and systemic drugs are currently used to prevent or treat BPD. Despite some positive effects on BPD, more information about the effects of inhaled corticosteroids is required to assess overall efficacy and associated risks. One needs to balance the risks of neurodevelopmental impairment owing to systemic corticosteroids against those of BPD itself. Future studies should, therefore, focus on infants with a very high risk of developing BPD and include pharmacokinetics and long-term developmental outcomes.
引用
收藏
页码：1355 / +
页数：14
相关论文
共 50 条
  • [11] Systemic Postnatal Corticosteroids, Bronchopulmonary Dysplasia, and Survival Free of Cerebral Palsy
    Doyle, Lex W.
    Mainzer, Rheanna
    Cheong, Jeanie L. Y.
    JAMA PEDIATRICS, 2025, 179 (01) : 65 - 72
  • [12] Orphan drugs in bronchopulmonary dysplasia
    Greenough, Anne
    Bhat, Prashanth
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (05): : 351 - 358
  • [13] Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part II. Inhaled corticosteroids alone or in combination with surfactants
    Szabo, Hajnalka
    Baraldi, Eugenio
    Colin, Andrew A.
    PEDIATRIC PULMONOLOGY, 2022, 57 (04) : 787 - 795
  • [14] Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
    Shah, S. S.
    Ohlsson, A.
    Halliday, H. L.
    Shah, V. S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [15] Policy Statement-Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
    Watterberg, Kristi L.
    Papile, Lu-Ann
    Adamkin, David H.
    Baley, Jill E.
    Bhutani, Vinod K.
    Carlo, Waldemar A.
    Kumar, Praveen
    Polin, Richard A.
    Tan, Rosemarie C.
    Wang, Kasper S.
    Watterberg, Kristi L.
    PEDIATRICS, 2010, 126 (04) : 800 - 808
  • [16] Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia
    Pantalitschka, T.
    Poets, C. F.
    PEDIATRIC PULMONOLOGY, 2006, 41 (08) : 703 - 708
  • [17] Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby
    Rostas, Sara E.
    McPherson, Christopher
    NEONATAL NETWORK, 2016, 35 (04): : 234 - 239
  • [18] Systemic Corticosteroids to Prevent Bronchopulmonary Dysplasia: Balancing Risk and Reward
    Jensen, Erik A.
    JAMA PEDIATRICS, 2025, 179 (01) : 9 - 10
  • [19] Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia
    Mandell, Erica W.
    Kratimenos, Panagiotis
    Abman, Steven H.
    Steinhorn, Robin H.
    CLINICS IN PERINATOLOGY, 2019, 46 (02) : 291 - +
  • [20] Systemic Hypertension in Infants with Bronchopulmonary Dysplasia
    Starr, Michelle C.
    Wilson, Amy C.
    CURRENT HYPERTENSION REPORTS, 2022, 24 (06) : 193 - 203
12345